Literature DB >> 17999741

Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner.

Luciano Vellon1, Javier A Menendez, Hong Liu, Ruth Lupu.   

Abstract

alpha(v)beta(3) integrin has a dual role in apoptosis. Whereas ligated alpha(v)beta(3) activates cell survival pathways and suppresses pro-apoptotic signals, unligated alpha(v)beta(3) or integrins bound to soluble ligands promote apoptosis. In this study, we assessed the role of alpha(v)beta(3) in chemosensitivity of breast cancer cells expressing different levels of heregulin (HRG). Expression levels of the RGD-binding integrins alpha(v)beta(3) were measured in MDA-MB-231 human breast cancer cells and its low HRG-expressing derivative (MDA-MB-231/AS31) treated with the microtubule-interfering agents (MIAs) paclitaxel and vincristine. Following treatment, only alpha(v)beta(3) levels were significantly increased in MDA-MB-231 cells. Interestingly, alpha(v)beta(3) expression was more significantly up-regulated in the MDA-MB-231/AS31 cells than in the parental cells. This MIA-induced increase of alpha(v)beta(3) expression was correlated with a decrease in cell viability and an increase in apoptosis in MDA-MB-231/AS31 cells, indicating that overexpression of alpha(v)beta(3) is linked to chemotherapy-induced cell death in low HRG-expressing breast cancer models. Moreover, a paclitaxel-induced increase of alpha(v)beta(3) was also observed in MCF-7 cells but not in an doxorubicin-resistant derivative that shows cross-resistance to paclitaxel, further providing evidence that the extent of alpha(v)beta(3) up-regulation is related to cell damage. These results indicate that alpha(v)beta(3) integrin is dramatically up-regulated in low HRG-expressing breast cancer models that are highly responsive to MIAs, thus providing a novel molecular marker of chemosensitivity influenced by HRG levels in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999741     DOI: 10.1111/j.1432-0436.2007.00241.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  12 in total

1.  Targeted fluorescent magnetic nanoparticles for imaging of human breast cancer.

Authors:  Jing Sun; Zhao-Gang Teng; Ying Tian; Jian-Dong Wang; Yang Guo; Dong-Hyun Kim; Andrew C Larson; Guang-Ming Lu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.

Authors:  Anat Eldar-Boock; Keren Miller; Joaquin Sanchis; Ruth Lupu; María J Vicent; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-04       Impact factor: 12.479

3.  Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.

Authors:  Amanda M Hamilton; Sallouha Aidoudi-Ahmed; Shweta Sharma; Venkata R Kotamraju; Paula J Foster; Kazuki N Sugahara; Erkki Ruoslahti; Brian K Rutt
Journal:  J Mol Med (Berl)       Date:  2015-04-14       Impact factor: 4.599

4.  A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors.

Authors:  Qixian Chen; Ruogu Qi; Xiyi Chen; Xi Yang; Sudong Wu; Haihua Xiao; Wenfei Dong
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

5.  Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells.

Authors:  Zhe Wang; Wai-Keung Chui; Paul C Ho
Journal:  Pharm Res       Date:  2009-02-04       Impact factor: 4.200

6.  Genetic Encoding of Targeted Magnetic Resonance Imaging Contrast Agents for Tumor Imaging.

Authors:  Simone Schuerle; Maiko Furubayashi; Ava P Soleimany; Tinotenda Gwisai; Wei Huang; Christopher Voigt; Sangeeta N Bhatia
Journal:  ACS Synth Biol       Date:  2020-01-22       Impact factor: 5.110

7.  Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases.

Authors:  Gregory C Fox; Xinming Su; Jennifer L Davis; Yalin Xu; Kristin A Kwakwa; Michael H Ross; Francesca Fontana; Jingyu Xiang; Alison K Esser; Elizabeth Cordell; Kristen Pagliai; Ha X Dang; Jothilingam Sivapackiam; Sheila A Stewart; Christopher A Maher; Suzanne J Bakewell; James A J Fitzpatrick; Vijay Sharma; Samuel Achilefu; Deborah J Veis; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Mol Cancer Ther       Date:  2021-03-30       Impact factor: 6.261

8.  External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.

Authors:  Karolina Partheen; Kristina Levan; Lovisa Osterberg; Ingela Claesson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-09-23       Impact factor: 4.430

Review 9.  Exploring the Role of RGD-Recognizing Integrins in Cancer.

Authors:  Markus Nieberler; Ute Reuning; Florian Reichart; Johannes Notni; Hans-Jürgen Wester; Markus Schwaiger; Michael Weinmüller; Andreas Räder; Katja Steiger; Horst Kessler
Journal:  Cancers (Basel)       Date:  2017-09-04       Impact factor: 6.639

10.  RGD conjugated cell uptake off to on responsive NIR-AZA fluorophores: applications toward intraoperative fluorescence guided surgery.

Authors:  Dan Wu; Harrison C Daly; Marco Grossi; Emer Conroy; Bo Li; William M Gallagher; Robert Elmes; Donal F O'Shea
Journal:  Chem Sci       Date:  2019-06-21       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.